• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Annual report of the Australian Gonococcal Surveillance Programme, 2002.

出版信息

Commun Dis Intell Q Rep. 2003;27(2):189-95. doi: 10.33321/cdi.2003.27.43.

DOI:10.33321/cdi.2003.27.43
PMID:12926734
Abstract

The Australian Gonococcal Surveillance Programme (AGSP) monitors the antibiotic susceptibility of Neisseria gonorrhoeae isolated in all states and territories. In 2002 the in vitro susceptibility of 3,861 isolates of gonococci from public and private sector sources was determined by standardised methods. Antibiotic susceptibility patterns again varied considerably between jurisdictions and regions. Resistance to the penicillins nationally was at 18 per cent but ranged up to 22 per cent in larger urban centres. Quinolone resistance in gonococci (QRNG) remained widespread. Nationally 10 per cent of all isolates were QRNG, and most of this resistance was at high MIC levels. All isolates remained sensitive to spectinomycin. A small number of isolates demonstrated some decreased susceptibility to ceftriaxone (MIC 0.06 mg/L or more) and were concentrated in New South Wales. Patterns of infection were unaltered from previous years. A high proportion of gonococci examined in larger urban centres were from male patients and rectal and pharyngeal isolates were common. In other centres and in rural Australia the male to female ratio of cases was lower, and most isolates were from the genital tract.

摘要

相似文献

1
Annual report of the Australian Gonococcal Surveillance Programme, 2002.
Commun Dis Intell Q Rep. 2003;27(2):189-95. doi: 10.33321/cdi.2003.27.43.
2
Annual report of the Australian Gonococcal Surveillance Programme, 2003.2003年澳大利亚淋球菌监测项目年度报告
Commun Dis Intell Q Rep. 2004;28(2):187-93. doi: 10.33321/cdi.2004.28.16.
3
Annual report of the Australian Gonococcal Surveillance Programme, 2001.《2001年澳大利亚淋球菌监测项目年度报告》
Commun Dis Intell Q Rep. 2002;26(2):242-7. doi: 10.33321/cdi.2002.26.20.
4
Annual report of the Australian Gonococcal Surveillance Programme, 2004.《2004年澳大利亚淋球菌监测项目年度报告》
Commun Dis Intell Q Rep. 2005;29(2):137-42. doi: 10.33321/cdi.2005.29.12.
5
Annual report of the Australian Gonococcal Surveillance Programme, 2000.《2000年澳大利亚淋球菌监测项目年度报告》
Commun Dis Intell Q Rep. 2001 Apr;25(2):59-63. doi: 10.33321/cdi.2001.25.12.
6
Annual Report of the Australian Gonococcal Surveillance Programme, 2009.《2009年澳大利亚淋球菌监测项目年度报告》
Commun Dis Intell Q Rep. 2010 Jun;34(2):89-95. doi: 10.33321/cdi.2010.34.12.
7
Annual report of the Australian Gonococcal Surveillance Programme, 2008.2008年澳大利亚淋球菌监测项目年度报告。
Commun Dis Intell Q Rep. 2009 Sep;33(3):268-74. doi: 10.33321/cdi.2009.33.29.
8
Annual report of the Australian Gonococcal Surveillance Programme, 2005.《2005年澳大利亚淋球菌监测项目年度报告》
Commun Dis Intell Q Rep. 2006;30(2):205-10. doi: 10.33321/cdi.2006.30.16.
9
Annual report of the Australian Gonococcal Surveillance Programme, 2007.2007年澳大利亚淋球菌监测项目年度报告
Commun Dis Intell Q Rep. 2008 Jun;32(2):227-31. doi: 10.33321/cdi.2008.32.20.
10
Annual report of the Australian Gonococcal Surveillance Programme, 2006.2006年澳大利亚淋球菌监测项目年度报告
Commun Dis Intell Q Rep. 2007 Jun;31(2):180-4. doi: 10.33321/cdi.2007.31.13.

引用本文的文献

1
Policy, practice, and prediction: model-based approaches to evaluating N. gonorrhoeae antibiotic susceptibility test uptake in Australia.政策、实践与预测:基于模型的方法评估澳大利亚淋病奈瑟菌抗生素药敏试验采用率
BMC Infect Dis. 2024 May 17;24(1):498. doi: 10.1186/s12879-024-09393-y.
2
Trends in Antimicrobial Resistance Patterns in Neisseria Gonorrhoeae in Australia and New Zealand: A Meta-analysis and Systematic Review.澳大利亚和新西兰淋病奈瑟菌抗菌药物耐药模式的趋势:一项荟萃分析和系统评价
Antibiotics (Basel). 2019 Oct 23;8(4):191. doi: 10.3390/antibiotics8040191.